newsfilter
← Latest News
Business Wire·

Robbins Umeda LLP Announces an Investigation of BioMimetic Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at BioMimetic Therapeutics, Inc. (NASDAQ: BMTI). BioMimetic Therapeutics is a biotechnology company specializing in the development and commercialization of regenerative protein drug-device products for the repair of orthopedic injuries. The company's primary product is AugmentTM Bone Graft, a fully synthetic treatment for bone injuries and defects. The company was founded in 1999, and is headquartered in Franklin, Tennessee.